Literature DB >> 22121083

miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells.

Ke Xu1, Xin Liang, Daling Cui, Yixin Wu, Weibin Shi, Jianwen Liu.   

Abstract

Colorectal carcinoma is a frequent cause of cancer-related death in the world for men and women. microRNAs are endogenous small noncoding RNAs that regulate gene expression negatively at post-transcriptional level. Here, we investigated the possible role of microRNAs in the development of multidrug resistance (MDR) in colorectal carcinoma cells. We analyzed microRNA (miRNA) expression levels between multidrug resistant colorectal carcinoma cell line HCT116/L-OHP and its parent cell line HCT116 using a miRNA microarray. miR-1915 had the lowest expression of miRNA in HCT116/L-OHP cells compared to its parental cells. Overexpression of Bcl-2 is generally associated with tumor drug resistance, meanwhile Bcl-2 is a predicted target of miR-1915. We found that elevated levels of miR-1915 in the mimics-transfected HCT116/L-OHP cells reduced Bcl-2 protein level and the luciferase activity of a Bcl-2 3'-untranslated region-based reporter, and also sensitized these cells to some anticancer drugs. Taken together, our findings suggest that miR-1915 could play a role in the development of MDR in colorectal carcinoma cells at least in part by modulation of apoptosis via targeting Bcl-2.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22121083     DOI: 10.1002/mc.21832

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  51 in total

Review 1.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  MicroRNAs are important regulators of drug resistance in colorectal cancer.

Authors:  Yang Zhang; Jing Wang
Journal:  Biol Chem       Date:  2017-07-26       Impact factor: 3.915

3.  miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.

Authors:  Ye Zhang; Xiujuan Qu; Ce Li; Yibo Fan; Xiaofang Che; Ximing Wang; Ying Cai; Xuejun Hu; Yunpeng Liu
Journal:  Tumour Biol       Date:  2014-11-19

Review 4.  The emerging role of noncoding RNAs in colorectal cancer chemoresistance.

Authors:  Ling Wei; Xingwu Wang; Liyan Lv; Yan Zheng; Nasha Zhang; Ming Yang
Journal:  Cell Oncol (Dordr)       Date:  2019-07-29       Impact factor: 6.730

Review 5.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

Review 6.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 7.  An update on microRNAs as colorectal cancer biomarkers: where are we and what's next?

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Ajay Goel
Journal:  Expert Rev Mol Diagn       Date:  2014-08-28       Impact factor: 5.225

Review 8.  MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity.

Authors:  Michael Hollis; Kavitha Nair; Arpita Vyas; Lakshmi Shankar Chaturvedi; Sahil Gambhir; Dinesh Vyas
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

9.  High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Authors:  Mads H Rasmussen; Niels F Jensen; Line S Tarpgaard; Camilla Qvortrup; Maria U Rømer; Jan Stenvang; Tine P Hansen; Lise L Christensen; Jan Lindebjerg; Flemming Hansen; Benny V Jensen; Torben F Hansen; Per Pfeiffer; Nils Brünner; Torben F Ørntoft; Claus L Andersen
Journal:  Mol Oncol       Date:  2013-02-28       Impact factor: 6.603

10.  miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1.

Authors:  Li Zhou; Tianzhu Qiu; Jing Xu; Tongshan Wang; Jian Wang; Xin Zhou; Zebo Huang; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  Pathol Oncol Res       Date:  2013-05-03       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.